Abeona Therapeutics Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 39.7 million compared to USD 84.94 million a year ago. Basic loss per share from continuing operations was USD 5.53 compared to USD 21.57 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.395 USD | -2.77% | +7.56% | -11.98% |
May. 30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
May. 16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.98% | 186M | |
+43.96% | 56.65B | |
-6.62% | 39.44B | |
+38.56% | 39.03B | |
-11.17% | 26.86B | |
+13.49% | 26.75B | |
-21.66% | 19.03B | |
+1.63% | 12.28B | |
+24.86% | 12.26B | |
+27.71% | 12.04B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022